` CVAC (CureVac NV) vs S&P 500 Comparison - Alpha Spread

CVAC
vs
S&P 500

Over the past 12 months, CVAC has significantly outperformed S&P 500, delivering a return of +62% compared to the S&P 500's +14% growth.

Stocks Performance
CVAC vs S&P 500

Loading
CVAC
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CVAC vs S&P 500

Performance Gap Between CVAC and GSPC
HIDDEN
Show

Performance By Year
CVAC vs S&P 500

Loading
CVAC
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
CureVac NV vs Peers

S&P 500
CVAC
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

CureVac NV
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

CVAC Intrinsic Value
HIDDEN
Show
Back to Top